Simionescu A, Streinu-Cercel A, Popescu F, Stanescu A, Vieru M, Danciu B
J Pers Med. 2021; 11(11).
PMID: 34834548
PMC: 8623700.
DOI: 10.3390/jpm11111196.
Nelson C, Herold B, Permar S
NPJ Vaccines. 2018; 3:38.
PMID: 30275984
PMC: 6148244.
DOI: 10.1038/s41541-018-0074-4.
Adler S, Manganello A, Lee R, McVoy M, Nixon D, Plotkin S
J Infect Dis. 2016; 214(9):1341-1348.
PMID: 27521362
PMC: 5079366.
DOI: 10.1093/infdis/jiw365.
Bialas K, Swamy G, Permar S
Clin Perinatol. 2015; 42(1):61-75, viii.
PMID: 25677997
PMC: 4328139.
DOI: 10.1016/j.clp.2014.10.006.
Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C
PLoS Pathog. 2014; 10(11):e1004524.
PMID: 25412505
PMC: 4239111.
DOI: 10.1371/journal.ppat.1004524.
Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface.
Schleiss M
Expert Opin Ther Pat. 2010; 20(4):597-602.
PMID: 20302454
PMC: 3539785.
DOI: 10.1517/13543770903584882.
Cytomegalovirus vaccines: at last, a major step forward.
Schleiss M
Herpes. 2009; 15(3):44-5.
PMID: 19306601
PMC: 4385584.
Immunobiology of human cytomegalovirus: from bench to bedside.
Crough T, Khanna R
Clin Microbiol Rev. 2009; 22(1):76-98, Table of Contents.
PMID: 19136435
PMC: 2620639.
DOI: 10.1128/CMR.00034-08.
Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus.
Zhong J, Rist M, Cooper L, Smith C, Khanna R
PLoS One. 2008; 3(9):e3256.
PMID: 18806877
PMC: 2533118.
DOI: 10.1371/journal.pone.0003256.
Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients.
Cvetkovic R, Wellington K
Drugs. 2005; 65(6):859-78.
PMID: 15819597
DOI: 10.2165/00003495-200565060-00012.
The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.
Schleiss M, Bernstein D, McVoy M, Stroup G, Bravo F, Creasy B
Antiviral Res. 2005; 65(1):35-43.
PMID: 15652969
PMC: 2768478.
DOI: 10.1016/j.antiviral.2004.09.004.
A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.
Huang D, Wu J, Tyring S
J Infect. 2004; 49(3):179-209.
PMID: 15337336
PMC: 7126106.
DOI: 10.1016/j.jinf.2004.05.018.
Human cytomegalovirus: detection of congenital and perinatal infection in Argentina.
Distefano A, Alonso A, Martin F, Pardon F
BMC Pediatr. 2004; 4:11.
PMID: 15214967
PMC: 449715.
DOI: 10.1186/1471-2431-4-11.
Generation of a recombinant cytomegalovirus for expression of a hantavirus glycoprotein.
Rizvanov A, van Geelen A, Morzunov S, Otteson E, Bohlman C, Pari G
J Virol. 2003; 77(22):12203-10.
PMID: 14581557
PMC: 254267.
DOI: 10.1128/jvi.77.22.12203-12210.2003.
Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.
Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M
J Virol. 2003; 77(9):5226-40.
PMID: 12692225
PMC: 153951.
DOI: 10.1128/jvi.77.9.5226-5240.2003.
Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant.
Revello M, Gerna G
Clin Microbiol Rev. 2002; 15(4):680-715.
PMID: 12364375
PMC: 126858.
DOI: 10.1128/CMR.15.4.680-715.2002.
Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients.
Bueno J, Ramil C, Green M
Paediatr Drugs. 2002; 4(5):279-90.
PMID: 11994033
DOI: 10.2165/00128072-200204050-00001.
Active immunization in the United States: developments over the past decade.
Dennehy P
Clin Microbiol Rev. 2001; 14(4):872-908, table of contents.
PMID: 11585789
PMC: 89007.
DOI: 10.1128/CMR.14.4.872-908.2001.
Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression.
Pepperl S, Munster J, Mach M, Harris J, Plachter B
J Virol. 2000; 74(13):6132-46.
PMID: 10846097
PMC: 112112.
DOI: 10.1128/jvi.74.13.6132-6146.2000.
